Key Developments: Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

22 May 2015
Change (% chg)

Rs18.60 (+0.51%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Ltd recommends final dividend
Tuesday, 12 May 2015 03:46am EDT 

Dr.Reddy's Laboratories Ltd:Recommends final dividend of 20 Indian rupees (400 pct) per equity share of 5 Indian rupees face value, for FY 2014-15.  Full Article

Dr.Reddy's Laboratories Ltd files three new drug applications with USFDA - PTI
Tuesday, 7 Apr 2015 10:49pm EDT 

Dr.Reddy's Laboratories Ltd:Has filed three new drug applications (NDAs), aimed to be used in the treatments of psoriasis, rosacea, migraine, with the US health regulator - PTI.The company and its subsidiary, Promius Pharma LLC have filed three new drug applications with the US Food and Drug Administration (USFDA).The three NDAs - DFD-01, DFD-09, and DFN-11 is focused on developing and commercialising therapies in dermatology and neurology.Upon approval, the products will be commercialised by Promius Pharma.  Full Article

Taxus Cardium Pharmaceuticals Group Inc announces agreement with Dr. Reddy's Laboratories Ltd
Tuesday, 7 Apr 2015 09:00am EDT 

Taxus Cardium Pharmaceuticals Group Inc:Has entered into binding term sheet with Dr.Reddy's Laboratories Ltd.For an exclusive territorial license covering the co-development, marketing and sales of the Generx [Ad5FGF-4] angiogenic microvascular gene therapy Phase 3 product candidate for patients with refractory angina, and myocardial ischemia due to cardiac microvascular insufficiency (CMI).Agreement initially covers certain territories and international markets, including Russia, Commonwealth of Independent States (CIS), Venezuela, Vietnam and Myanmar.And provides right of first refusal for Dr. Reddy's Laboratories to negotiate additional exclusive license agreements to market and sell the Generx gene therapy product candidate in over 30 other countries in Latin America and the Association of Southeast Asian Nations.  Full Article

Dr.Reddy's Laboratories Ltd to acquire select portfolio
Wednesday, 1 Apr 2015 02:56am EDT 

Dr.Reddy's Laboratories Ltd:Entered into a definitive agreement to acquire a select portfolio of the established products of UCB.The transaction includes about 350 employees engaged in operations of the India Business.The transaction is expected to closed in the first quarter of the financial year 2015-2016.  Full Article

Dr.Reddy's Laboratories Ltd enters into partnership with Hetero to accelerate access to treatment for Hepatitis C in India
Monday, 23 Mar 2015 06:41am EDT 

Dr.Reddy's Laboratories Ltd:Enters into an agreement with Hetero, under which it has been licensed to distribute and market Sofosbuvir 400 mg tablets1, indicated in treatment of Chronic Hepatitis C, under brand name Resof, in India.  Full Article

Dr.Reddy's Laboratories Ltd closes the aquisition of Habitrol Brand from Novartis
Friday, 19 Dec 2014 12:11am EST 

Dr.Reddy's Laboratories Ltd:Says that it has closed the aquisition of Habitrol Brand (an over-the-counter nicotine replacement therapy transdermal patch) from Novartis Consumer Health Inc.Says with this closure the company has assumed the responsibility for the product and will commence shipments of the product in the market shortly.  Full Article

Dr.Reddy's Laboratories Ltd announces launch of Docetaxel Injection USP
Monday, 24 Nov 2014 01:00am EST 

Dr.Reddy's Laboratories Ltd:Announces that it has launched Docetaxel Injection USP 20mg/mL and 80mg/4 mL a therapeutic equivalent generic version of TAXOTERE in the US market on Nov. 21.  Full Article

Dr.Reddy's Laboratories Ltd launches organ transplant drug-Business Standard
Wednesday, 29 Oct 2014 09:46am EDT 

Dr.Reddy's Laboratories Ltd:Has launched Sirolimus tablets 1 mg and 2 mg, a therapeutic equivalent generic version of Rapamune tablets in the US market-Business Standard.  Full Article

Dr.Reddy's Laboratories Ltd announces launch of Duloxetine Delayed-Release Capsules USP
Friday, 27 Jun 2014 03:27am EDT 

Dr.Reddy's Laboratories Ltd:Launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, therapeutic equivalent generic version of CYMBALTA((reg))(Duloxetine Delayed-Release Capsules) in US market on June 26.Dr. Reddy's ANDA is approved by US Food & Drug Administration.  Full Article

Dr.Reddy's Laboratories Ltd launches Paricalcitol Capsules
Wednesday, 25 Jun 2014 02:01am EDT 

Dr.Reddy's Laboratories Ltd:Says the launch of Paricalcitol Capsules.  Full Article

Dr.Reddy's in talks to buy UCB India business for $135 mln - source

MUMBAI, March 10 - Indian drugmaker Dr.Reddy's Laboratories Ltd is in talks to acquire the Indian operations of Belgian pharmaceutical company UCB SA for about $135 million, said a person with direct knowledge of the matter.

Search Stocks